Filter Results:
- Full text PDF available (13)
Publication Year
1959
2017
- This year (0)
- Last 5 years (5)
- Last 10 years (31)
Publication Type
Co-author
Journals and Conferences
Brain Region
Organism
Learn More
- Ruth Duncan, Rogério S Gaspar
- Molecular pharmaceutics
- 2011
Depending on the context, nanotechnologies developed as nanomedicines (nanosized therapeutics and imaging agents) are presented as either a remarkable technological revolution already capable of… (More)
- Namita Malik, Ruedeekorn Wiwattanapatapee, +6 authors Ruth Duncan
- Journal of controlled release : official journal…
- 2000
Dendrimers are highly branched macromolecules of low polydispersity that provide many exciting opportunities for design of novel drug-carriers, gene delivery systems and imaging agents. They hold… (More)
- Sunil Shaunak, Sharyn Thomas, +9 authors Steve Brocchini
- Nature Biotechnology
- 2004
Dendrimers are hyperbranched macromolecules that can be chemically synthesized to have precise structural characteristics. We used anionic, polyamidoamine, generation 3.5 dendrimers to make novel… (More)
- Ruth Duncan, Lorella Izzo
- Advanced drug delivery reviews
- 2005
The field of biomedical dendrimers is still in its infancy, but the explosion of interest in dendrimers and dendronised polymers as inherently active therapeutic agents, as vectors for targeted… (More)
- Simon Richardson, Paolo Ferruti, Ruth Duncan
- Journal of drug targeting
- 1999
Fusogenic peptides derived from viral coat proteins cause perturbation of the endosomal membrane and are often used to improve the transfection efficiency of non-viral vectors in vitro. However,… (More)
- Ruth Duncan, Simon Richardson
- Molecular pharmaceutics
- 2012
More than 40 nanomedicines are already in routine clinical use with a growing number following in preclinical and clinical development. The therapeutic objectives are often enhanced disease-specific… (More)
- Rogério S Gaspar, Ruth Duncan
- Advanced drug delivery reviews
- 2009
Since the early 1990s polymer-protein conjugates (included PEGylated enzymes and cytokines), polymeric drugs and polymeric sequestrants have been entering the market as innovative polymer-based… (More)
- Ruth Duncan, Stéphanie Gac-Breton, +4 authors F Searle
- Journal of controlled release : official journal…
- 2001
There are now at least seven polymer-drug conjugates that have entered phase I/II clinical trial as anticancer agents. These include N-(2-hydroxypropyl)methacrylamide (HPMA) copolymer-doxorubicin… (More)
- Youichiro Noguchi, Jun Jing Wu, +4 authors Hiroshi Maeda
- Japanese journal of cancer research : Gann
- 1998
The objective of this study was to investigate the molecular weight (MW) and time-dependence of the phenomenon termed "the enhanced permeability and retention" (EPR) effect in solid tumor, in… (More)
- R Satchi, Thomas A. Connors, Ruth Duncan
- British Journal of Cancer
- 2001
Polymer-directed enzyme prodrug therapy (PDEPT) is a novel two-step antitumour approach using a combination of a polymeric prodrug and polymer-enzyme conjugate to generate cytotoxic drug selectively… (More)